Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Sandeep Gurbuxani

TitleProfessor
InstitutionUniversity of Chicago
DepartmentPathology
AddressChicago IL 60637
Phone+1 (773) 7027279
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    As an attending hematopathologist I am involved in diagnostic work up and follow up after therapy of patients diagnosed with hematologic malignancies including AML, ALL, MDS and MDS/MPN. I am interested in understanding the pathogenesis of hematopoietic tumors and how specific events required for leukemic transformation can be targeted for therapy. In addition, as part of collaborative research projects I have been involved in the analyses of mice in models of normal and malignant hematopoiesis.


    Collapse Biography 
    Collapse education and training
    Department of Pathology, Univeristy of Chicago , ChicagoFellowship12/2008Hematopathology
    Department of Pathology, Univeristy of Chicago, ChicagoResidency12/2007Clinical Pathology
    Ben May Department of Cancer Research, University of Chicago, ChicagoPost Doctoral Fellowship01/2004Cancer Biology, Normal and Malignant Hematopoiesis
    INSERM U517, University of Burgundy, Dijon, FrancePost Doctoral Fellowship05/2002Cancer Biology, Apoptosis
    All India Institute of Medical Sciences, New Delhi, IndiaPhD03/2000Hematology
    Motilal Nehru Medical College, Allahabad, IndiaMBBS06/1992Medicine

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. An N, Khan S, Imgruet MK, Jueng L, Gurbuxani S, McNerney ME. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene. 2023 Feb 01. PMID: 36725889.
      View in: PubMed
    2. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 Jan 19. PMID: 36655425.
      View in: PubMed
    3. Melo-Cardenas J, Bezavada L, Crawford JC, Gurbuxani S, Cotton A, Kang G, Gossett J, Marinaccio C, Weinberg R, Hoffman R, Migliaccio AR, Zheng Y, Derecka M, Rinaldi CR, Crispino JD. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 2022 12 29; 140(26):2805-2817. PMID: 36283106.
      View in: PubMed
    4. MacDonald ME, Weathered RK, Stewart EC, Magold AI, Mukherjee A, Gurbuxani S, Smith H, McMullen P, Mueller J, Husain AN, Salles CM, Briquez PS, Rouhani SJ, Yu J, Trujillo J, Pyzer AR, Gajewski TF, Sperling AI, Kilarski WW, Swartz MA. Lymphatic coagulation and neutrophil extracellular traps in?lung-draining lymph nodes of COVID-19 decedents. Blood Adv. 2022 12 27; 6(24):6249-6262. PMID: 35977099.
      View in: PubMed
    5. Ling T, Zhang K, Yang J, Gurbuxani S, Crispino JD. Gata1s mutant mice display persistent defects in the erythroid lineage. Blood Adv. 2022 Nov 09. PMID: 36350717.
      View in: PubMed
    6. Alban J, DuVall A, Gurbuxani S, Stock W, Patel AA. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353. PMID: 36240471.
      View in: PubMed
    7. Spring J, Khan AA, Lara S, O'Grady K, Wilks J, Gurbuxani S, Erickson S, Fischbach M, Jacobson A, Chervonsky A, Golovkina T. Gut commensal bacteria enhance pathogenesis of a tumorigenic murine retrovirus. Cell Rep. 2022 09 13; 40(11):111341. PMID: 36103821.
      View in: PubMed
    8. Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286. PMID: 35862034.
      View in: PubMed
    9. Kaumeyer BA, Fidai SS, Thakral B, Wang SA, Arber DA, Cheng JX, Gurbuxani S, Venkataraman G. GLUT1 Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues. Am J Clin Pathol. 2022 08 04; 158(2):228-234. PMID: 35311938.
      View in: PubMed
    10. Ibarra J, Elbanna YA, Kurylowicz K, Ciboddo M, Greenbaum HS, Arellano NS, Rodriguez D, Evers M, Bock-Hughes A, Liu C, Smith Q, Lutze J, Baumeister J, Kalmer M, Olschok K, Nicholson B, Silva D, Maxwell L, Dowgielewicz J, Rumi E, Pietra D, Casetti IC, Catricala S, Koschmieder S, Gurbuxani S, Schneider RK, Oakes SA, Elf SE. Type I but Not Type II Calreticulin Mutations Activate the IRE1a/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Blood Cancer Discov. 2022 07 06; 3(4):298-315. PMID: 35405004.
      View in: PubMed
    11. Wang P, Segal J, Drazer MW, Venkataraman G, Arber DA, Gurbuxani S. NPM1 exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring. EJHaem. 2022 Aug; 3(3):962-965. PMID: 36051025.
      View in: PubMed
    12. Siddiqui F, Perez Silos V, Karube K, Yasin Goksu S, Nandakumar S, Saygin C, Onajin O, Prabu SS, Gurbuxani S, Arber DA, Tjota M, Segal J, Smith SM, Murga-Zamalloa CA, Venkataraman G. B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas. Hum Pathol. 2022 07; 125:48-58. PMID: 35452696.
      View in: PubMed
    13. Tariq H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, Segal J, Gurbuxani S, Helenowski IB, Zhang H, Sukhanova M, Lu X, Altman JK, Chen QC, Behdad A. Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022 06; 197(6):736-744. PMID: 35304738.
      View in: PubMed
    14. Kaumeyer B, Fidai S, Sukhanova M, Yap KL, Segal J, Raca G, Stock W, McNeer J, Lager AM, Gurbuxani S. MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444. PMID: 35171727.
      View in: PubMed
    15. Gao J, Gurbuxani S, Zak T, Kocherginsky M, Ji P, Wehbe F, Chen Q, Chen YH, Lu X, Jennings L, Frankfurt O, Altman J, Sukhanova M. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation. Genes Chromosomes Cancer. 2022 02; 61(2):71-80. PMID: 34668265.
      View in: PubMed
    16. Imgruet MK, Lutze J, An N, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher D, Gurbuxani SK, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 09 02; 138(9):790-805. PMID: 34473231.
      View in: PubMed
    17. Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock W. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420. PMID: 35844676.
      View in: PubMed
    18. Imgruet MK, Lutze J, An NN, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher DJ, Gurbuxani S, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetic-driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 May 26. PMID: 34041524.
      View in: PubMed
    19. Takeda MR, Gurbuxani S. bcr3 PML-RARA: short fusion, small blasts! Blood. 2021 05 13; 137(19):2708. PMID: 33983418.
      View in: PubMed
    20. McMullen P, Pytel P, Snyder A, Smith H, Vickery J, Brainer J, Guzy R, Wu D, Schoettler N, Adegunsoye A, Sperling A, Hart J, Alpert L, Chang A, Gurbuxani S, Krausz T, Husain AN, Mueller J. A series of COVID-19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza. J Pathol Clin Res. 2021 09; 7(5):459-470. PMID: 33960723.
      View in: PubMed
    21. Marinaccio C, Suraneni P, Celik H, Volk A, Wen QJ, Ling T, Bulic M, Lasho T, Koche RP, Famulare CA, Farnoud N, Stein B, Schieber M, Gurbuxani S, Root DE, Younger ST, Hoffman R, Gangat N, Ntziachristos P, Chandel NS, Levine RL, Rampal RK, Challen GA, Tefferi A, Crispino JD. LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discov. 2021 06; 11(6):1398-1410. PMID: 33579786.
      View in: PubMed
    22. Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523. PMID: 32735641.
      View in: PubMed
    23. Gurbuxani S. CXCL4's "Gliful" subversion of BM in MPN. Blood. 2020 10 29; 136(18):1999-2000. PMID: 33119760.
      View in: PubMed
    24. Parilla M, Gurbuxani S. Red cell morphology in sickle cell disease. Blood. 2020 10 15; 136(16):1893. PMID: 33057703.
      View in: PubMed
    25. Feurstein S, Adegunsoye A, Mojsilovic D, Vij R, West DePersia AH, Rajagopal PS, Osman A, Collins RH, Kim RH, Gore SD, Greenberg P, Godley LA, Li Z, Del Gaudio D, Subramanian HP, Das S, Walsh T, Gulsuner S, Segal JP, Husain AN, Gurbuxani S, King MC, Strek ME, Churpek JE. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv. 2020 10 13; 4(19):4873-4886. PMID: 33035329.
      View in: PubMed
    26. Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike O. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51. PMID: 32358888.
      View in: PubMed
    27. Gurbuxani S. Lymphoblastic leukemia following MDS or MDS/MPN: clinical evidence for stem cell origins of these disorders. Leuk Lymphoma. 2019 12; 60(12):2847-2848. PMID: 31556763.
      View in: PubMed
    28. Sundaravel S, Kuo WL, Jeong JJ, Choudhary GS, Gordon-Mitchell S, Liu H, Bhagat TD, McGraw KL, Gurbuxani S, List AF, Verma A, Wickrema A. Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. Clin Cancer Res. 2019 09 15; 25(18):5638-5649. PMID: 31308061.
      View in: PubMed
    29. Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019 Aug 15; 25(16):4898-4906. PMID: 31061068.
      View in: PubMed
    30. Cracolici V, Gurbuxani S, Ginat DT. Head and Neck Sinus Histiocytosis with Massive Lymphadenopathy Radiology-Pathology Correlation. Head Neck Pathol. 2019 Dec; 13(4):656-660. PMID: 29855802.
      View in: PubMed
    31. An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018 06 14; 131(24):2682-2697. PMID: 29592892.
      View in: PubMed
    32. Nassin ML, Nicolaou E, Gurbuxani S, Cohn SL, Cunningham JM, LaBelle JL. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. Biol Blood Marrow Transplant. 2018 03; 24(3):452-459. PMID: 29191664.
      View in: PubMed
    33. Cracolici V, Grogan RH, Sukhanova M, Cheng JX, Gurbuxani S, Cipriani NA. A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands. Head Neck Pathol. 2018 Jun; 12(2):286-290. PMID: 29030756.
      View in: PubMed
    34. Gurbuxani S. The web of microRNA in B lymphoblastic leukemia. Leuk Lymphoma. 2017 09; 58(9):2024-2025. PMID: 28632459.
      View in: PubMed
    35. Edelblum KL, Sharon G, Singh G, Odenwald MA, Sailer A, Cao S, Ravens S, Thomsen I, El Bissati K, McLeod R, Dong C, Gurbuxani S, Prinz I, Mazmanian SK, Turner JR. The Microbiome Activates CD4 T-cell-mediated Immunity to?Compensate for Increased Intestinal Permeability. Cell Mol Gastroenterol Hepatol. 2017 Sep; 4(2):285-297. PMID: 28795125.
      View in: PubMed
    36. Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, Migliaccio A, Gurbuxani S, Vainchenker W, Platanias LC, Tefferi A, Crispino JD. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017 Apr 03; 127(4):1316-1320. PMID: 28240607.
      View in: PubMed
    37. Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell. 2017 01 09; 31(1):127-141. PMID: 28017614.
      View in: PubMed
    38. Yap KL, Furtado LV, Kiyotani K, Curran E, Stock W, McNeer JL, Kadri S, Segal JP, Nakamura Y, Le Beau MM, Gurbuxani S, Raca G. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958. PMID: 27855558.
      View in: PubMed
    39. Arcipowski KM, Bulic M, Gurbuxani S, Licht JD. Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis. PLoS One. 2016; 11(9):e0162515. PMID: 27610619.
      View in: PubMed
    40. Alikhan M, Song JY, Sohani AR, Moroch J, Plonquet A, Duffield AS, Borowitz MJ, Jiang L, Bueso-Ramos C, Inamdar K, Menon MP, Gurbuxani S, Chan E, Smith SM, Nicolae A, Jaffe ES, Gaulard P, Venkataraman G. Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Mod Pathol. 2016 10; 29(10):1173-82. PMID: 27312067.
      View in: PubMed
    41. Jiang X, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J. Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res. 2016 08 01; 76(15):4470-80. PMID: 27280396.
      View in: PubMed
    42. Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016 04 26; 7:11452. PMID: 27116251.
      View in: PubMed
    43. Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J. Identification of MLL-fusion/MYC?miR-26?TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 2016 Mar 28; 372(2):157-65. PMID: 26791235.
      View in: PubMed
    44. Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. Cancer Res. 2016 Feb 01; 76(3):619-29. PMID: 26747896.
      View in: PubMed
    45. Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80. PMID: 26569382.
      View in: PubMed
    46. Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015 Oct 22; 126(17):2005-15. PMID: 26361793.
      View in: PubMed
    47. Xu Y, Evaristo C, Alegre ML, Gurbuxani S, Kee BL. Analysis of GzmbCre as a Model System for Gene Deletion in the Natural Killer Cell Lineage. PLoS One. 2015; 10(4):e0125211. PMID: 25923440.
      View in: PubMed
    48. Raca G, Gurbuxani S, Zhang Z, Li Z, Sukhanova M, McNeer J, Stock W. RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr; 56(4):1145-7. PMID: 25098428.
      View in: PubMed
    49. Siu KT, Xu Y, Swartz KL, Bhattacharyya M, Gurbuxani S, Hua Y, Minella AC. Chromosome instability underlies hematopoietic stem cell dysfunction and lymphoid neoplasia associated with impaired Fbw7-mediated cyclin E regulation. Mol Cell Biol. 2014 Sep; 34(17):3244-58. PMID: 24958101.
      View in: PubMed
    50. McGregor S, Shah A, Raca G, Mirza MK, Smith SM, Anastasi J, Vardiman JW, Hyjek E, Gurbuxani S. PLZF staining identifies peripheral T-cell lymphomas derived from innate-like T-cells with TRAV1-2-TRAJ33 TCR-a rearrangement. Blood. 2014 Apr 24; 123(17):2742-3. PMID: 24764561.
      View in: PubMed
    51. Marquez R, Hantel A, Lorenz R, Neistadt B, Wong J, Churpek JE, Mardini NA, Shaukat I, Gurbuxani S, Miller JL, Godley LA. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6. PMID: 24628296.
      View in: PubMed
    52. Kamran Mirza M, Gurbuxani S. Cloaked in a starry sky. Blood. 2014 Apr 10; 123(15):2291. PMID: 24895700.
      View in: PubMed
    53. Huang H, Jiang X, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin P, Liu PP, Rowley JD, Xu M, He C, Chen J. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11994-9. PMID: 23818607.
      View in: PubMed
    54. Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, He C, Gurbuxani S, Kunjamma RB, Huang H, Jiang X, Arnovitz S, Xu M, Hong GM, Elkahloun AG, Neilly MB, Wunderlich M, Larson RA, Le Beau MM, Mulloy JC, Liu PP, Rowley JD, Chen J. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):11511-6. PMID: 23798388.
      View in: PubMed
    55. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43. PMID: 23771005.
      View in: PubMed
    56. Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, Levine RL, Tefferi A, Crispino JD. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Sep; 27(9):1882-90. PMID: 23748344.
      View in: PubMed
    57. Fox MF, Pontier A, Gurbuxani S, Sipkins DA. Stem cell factor expression in B cell malignancies is influenced by the niche. Leuk Lymphoma. 2013 Oct; 54(10):2274-80. PMID: 23418895.
      View in: PubMed
    58. van Slambrouck CM, Gurbuxani S. On a WHIM. Blood. 2013 Feb 07; 121(6):875. PMID: 23520626.
      View in: PubMed
    59. Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19397-402. PMID: 23132946.
      View in: PubMed
    60. Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews JM, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, Chen J. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012 Oct 16; 22(4):524-35. PMID: 23079661.
      View in: PubMed
    61. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. PMID: 21913806.
      View in: PubMed
    62. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012 Mar; 122(3):948-62. PMID: 22354171.
      View in: PubMed
    63. McGregor S, McNeer J, Gurbuxani S. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. Semin Diagn Pathol. 2012 Feb; 29(1):2-11. PMID: 22372201.
      View in: PubMed
    64. Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24. PMID: 21421111.
      View in: PubMed
    65. Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010 Nov; 24(11):1920-6. PMID: 20882051.
      View in: PubMed
    66. Huang QQ, Perlman H, Huang Z, Birkett R, Kan L, Agrawal H, Misharin A, Gurbuxani S, Crispino JD, Pope RM. FLIP: a novel regulator of macrophage differentiation and granulocyte homeostasis. Blood. 2010 Dec 02; 116(23):4968-77. PMID: 20724542.
      View in: PubMed
    67. Ferguson SD, Musleh W, Gurbuxani S, Shafizadeh SF, Lesniak MS. Intracranial mucosa-associated lymphoid tissue (MALT) lymphoma. J Clin Neurosci. 2010 May; 17(5):666-9. PMID: 20202849.
      View in: PubMed
    68. Gao Z, Huang Z, Olivey HE, Gurbuxani S, Crispino JD, Svensson EC. FOG-1-mediated recruitment of NuRD is required for cell lineage re-enforcement during haematopoiesis. EMBO J. 2010 Jan 20; 29(2):457-68. PMID: 20010697.
      View in: PubMed
    69. Gurbuxani S, Gurbaxani S, Anastasi J, Hyjek E. Diffuse large B-cell lymphoma--more than a diffuse collection of large B cells: an entity in search of a meaningful classification. Arch Pathol Lab Med. 2009 Jul; 133(7):1121-34. PMID: 19642739.
      View in: PubMed
    70. Rosen DS, Smith S, Gurbuxani S, Yamini B. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine. 2008 Oct; 9(4):374-6. PMID: 18939925.
      View in: PubMed
    71. Dias S, M?nsson R, Gurbuxani S, Sigvardsson M, Kee BL. E2A proteins promote development of lymphoid-primed multipotent progenitors. Immunity. 2008 Aug 15; 29(2):217-27. PMID: 18674933.
      View in: PubMed
    72. Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008 Jan 15; 111(2):767-75. PMID: 17901249.
      View in: PubMed
    73. Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, Crispino JD. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med. 2007 Jul 09; 204(7):1603-11. PMID: 17576776.
      View in: PubMed
    74. Gurbuxani S, Miller JL. Resident training in laboratory hematology. Clin Lab Med. 2007 Jun; 27(2):359-68; abstract vii-viii. PMID: 17556089.
      View in: PubMed
    75. Gurbuxani S, Anastasi J. What to do when you suspect gastrointestinal lymphoma: a pathologist's perspective. Clin Gastroenterol Hepatol. 2007 Apr; 5(4):417-21. PMID: 17336592.
      View in: PubMed
    76. Gurbuxani S. WT1 expression in myelodysplastic syndrome. Leuk Lymphoma. 2007 Mar; 48(3):456-7. PMID: 17454584.
      View in: PubMed
    77. Kircher SM, Gurbuxani S, Smith SM. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):59-62. PMID: 19065726.
      View in: PubMed
    78. Kircher SM, Gurbuxani S, Smith SM. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):19-23. PMID: 19065718.
      View in: PubMed
    79. Gurbuxani S. CD36 - a marker for drug sensitive acute megakaryoblastic leukemia. Leuk Lymphoma. 2006 Oct; 47(10):2004-5. PMID: 17071466.
      View in: PubMed
    80. Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A. 2005 Aug 09; 102(32):11480-5. PMID: 16055565.
      View in: PubMed
    81. Schmitt E, Parcellier A, Ghiringhelli F, Casares N, Gurbuxani S, Droin N, Hamai A, Pequignot M, Hammann A, Moutet M, Fromentin A, Kroemer G, Solary E, Garrido C. Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C. Cancer Res. 2004 Apr 15; 64(8):2705-11. PMID: 15087383.
      View in: PubMed
    82. Schmitt E, Parcellier A, Gurbuxani S, Cande C, Hammann A, Morales MC, Hunt CR, Dix DJ, Kroemer RT, Giordanetto F, J??ttel? M, Penninger JM, Pance A, Kroemer G, Garrido C. Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res. 2003 Dec 01; 63(23):8233-40. PMID: 14678980.
      View in: PubMed
    83. Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003 Nov-Dec; 31(3):351-6. PMID: 14636651.
      View in: PubMed
    84. Gurbuxani S, Schmitt E, Cande C, Parcellier A, Hammann A, Daugas E, Kouranti I, Spahr C, Pance A, Kroemer G, Garrido C. Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene. 2003 Oct 02; 22(43):6669-78. PMID: 14555980.
      View in: PubMed
    85. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004 Jan 15; 103(2):399-406. PMID: 14512321.
      View in: PubMed
    86. Parcellier A, Schmitt E, Gurbuxani S, Seigneurin-Berny D, Pance A, Chant?me A, Plenchette S, Khochbin S, Solary E, Garrido C. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol. 2003 Aug; 23(16):5790-802. PMID: 12897149.
      View in: PubMed
    87. Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Commun. 2003 May 09; 304(3):505-12. PMID: 12729585.
      View in: PubMed
    88. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003 Jun 01; 101(11):4298-300. PMID: 12560215.
      View in: PubMed
    89. Gurbuxani S, Bruey JM, Fromentin A, Larmonier N, Parcellier A, J??ttel? M, Martin F, Solary E, Garrido C. Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. Oncogene. 2001 Nov 08; 20(51):7478-85. PMID: 11709719.
      View in: PubMed
    90. Bonnotte B, Larmonier N, Favre N, Fromentin A, Moutet M, Martin M, Gurbuxani S, Solary E, Chauffert B, Martin F. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol. 2001 Nov 01; 167(9):5077-83. PMID: 11673517.
      View in: PubMed
    91. Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, J??ttel? M, Penninger JM, Garrido C, Kroemer G. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol. 2001 Sep; 3(9):839-43. PMID: 11533664.
      View in: PubMed
    92. Garrido C, Gurbuxani S, Ravagnan L, Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun. 2001 Aug 24; 286(3):433-42. PMID: 11511077.
      View in: PubMed
    93. Sazawal S, Gurbuxani S, Bhatia K, Khattar A, Raina V, Arya LS, Vats T, Magrath I, Bhargava M. Incidence, clinical characteristics and early treatment outcome in Indian patients of childhood acute lymphoblastic leukemia with ALL-1 gene rearrangement. Leuk Res. 2001 Aug; 25(8):693-8. PMID: 11397475.
      View in: PubMed
    94. Gurbuxani S, Singh Arya L, Raina V, Sazawal S, Khattar A, Magrath I, Marie J, Bhargava M. Significance of MDR1, MRP1, GSTpi and GSTmu mRNA expression in acute lymphoblastic leukemia in Indian patients. Cancer Lett. 2001 Jun 10; 167(1):73-83. PMID: 11323101.
      View in: PubMed
    95. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G, Solary E, Garrido C. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol. 2000 Sep; 2(9):645-52. PMID: 10980706.
      View in: PubMed
    96. Sazawal S, Bhatia K, Gurbuxani S, Singh Arya L, Raina V, Khattar A, Vats T, Magrath I, Bhargava M. Pattern of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements in childhood acute lymphoblastic leukemia in India. Leuk Res. 2000 Jul; 24(7):575-82. PMID: 10867131.
      View in: PubMed
    97. Gurbuxani S, Sazawal S, Arya LS, Raina V, Marie JP, Bhargava M. MDR1 mRNA expression in young patients with acute lymphoblastic leukaemia. Br J Haematol. 2000 Jun; 109(4):897-9. PMID: 10970135.
      View in: PubMed
    98. Gurbuxani S, Zhou D, Simonin G, Raina V, Arya LS, Sazawal S, Marie JP, Bhargava M. Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India. Ann Hematol. 1998 May; 76(5):195-200. PMID: 9671132.
      View in: PubMed
    99. Dutta U, Raina V, Garg PK, Gurbuxani S, Joshi YK, Bhargava M, Tandon RK. A prospective study on the incidence of hepatitis B & C infections amongst patients with lymphoproliferative disorders. Indian J Med Res. 1998 Feb; 107:78-82. PMID: 9540281.
      View in: PubMed
    100. Gurbuxani S, Lacorte JM, Raina V, Arya LS, Pepin D, Sazawal S, Marie JP, Bhargava M. Detection of BCR-ABL transcripts in acute lymphoblastic leukemia in Indian patients. Leuk Res. 1998 Jan; 22(1):77-80. PMID: 9585083.
      View in: PubMed
    101. Legrand O, Perrot JY, Tang R, Simonin G, Gurbuxani S, Zittoun R, Marie JP. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol. 1996 Jul; 94(1):23-33. PMID: 8757504.
      View in: PubMed
    102. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer. 1996 Jun; 32A(6):1034-8. PMID: 8763345.
      View in: PubMed
    Gurbuxani's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (466) concept(s)
    _
    Co-Authors Expand Description
    See all (69) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _